



THE MISTERY OF GUSTAVE FLAUBERT’S DEATH
Could sudden unexpected death in epilepsy be part of the context?
Marly de Albuquerque1, Carla A. Scorza1, Ricardo M. Arida2, Esper A. Cavalheiro1, Fulvio A. Scorza1
Abstract – Epilepsy is the most common serious neurological condition and sudden unexpected death in 
epilepsy (SUDEP) is the most important direct epilepsy-related cause of death. Information concerning risk 
factors for SUDEP is conflicting, but high seizure frequency is a potential risk factor. Additionally, potential 
pathomechanisms for SUDEP are unknown, but it is very probable that cardiac arrhythmias during and between 
seizures or transmission of epileptic activity to the heart via the autonomic nervous system potentially play a 
role. More than two decades ago, temporal lobe epilepsy was suggested as having been the ‘‘nervous disease’’ 
of Gustave Flaubert, one of the most important French novelists. In these lines, as the circumstances of his 
death were the subject of fabulous and mysterious speculations, we postulated in this paper that Falubert’s 
death could be due SUDEP phenomenon.
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O mistério da morte de Gustave Flaubert: pode a morte súbita em epilepsia fazer parte o contexto ?
Resumo – A epilepsia é a condição neurológica crônica grave mais comum e a morte súbita em epilepsia 
(SUDEP) é a mais importante causa de morte diretamente relacionada à epilepsia. Informações sobre fatores 
de risco para SUDEP são conflitantes, porém, a alta freqüência de crises epilépticas é um fator de risco em 
potencial. Além disso, os mecanismos causais para SUDEP ainda não estão conhecidos, mas é muito provável 
que arritmias cardíacas durante e entre as crises epilépticas ou a transmissão da atividade epiléptica para o 
coração via sistema nervoso autônomo desempenhem um importante papel. Mais de duas décadas atrás, foi 
proposto que a “doença nervosa” de Gustave Flaubert, um dos mais importantes novelistas franceses, era 
epilepsia do lobo temporal. Nesse sentido, como a morte de Gustave Flaubert ainda seja motivo de misteriosa 
especulação, nosso artigo propõe que a mesma poderia estar relacionada ao fenômeno de SUDEP.
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EpILEpSY: GEnERAL ASpEcTS
Epilepsy is the most common serious neurological 
condition and approximately 50 million people world-
wide have it1. In the US, about 100,000 new cases of epi-
lepsy are diagnosed2,3. In the UK, between 1 in 140 and 1 in 
200 people (at least 300,000 people) are currently being 
treated for epilepsy4. Epidemiological studies suggest that 
between 70 and 80% of people developing epilepsy will 
go into remission, while the remaining patients contin-
ue to have seizures and are refractory to treatment with 
the currently available therapies5-7. The most common risk 
factors for epilepsy are cerebrovascular disease, brain tu-
mours, alcohol, traumatic head injuries, malformations of 
cortical development, genetic inheritance, and infections 
of the central nervous system. In resource-poor countries, 
endemic infections, such as malaria and neurocysticerco-
sis, seem to be major risk factors8.
Epilepsies are characterized by spontaneous recurrent 
seizures, caused by focal or generalized paroxysmal chang-
es in neurological functions triggered by abnormal electri-
cal activity in the cortex9. Because it involves hyperexcit-
able neurons, a basic assumption links the pathogenesis of 
epilepsy and the generation of synchronized neuronal ac-





tyric acid (GABA)-mediated] and excitatory (glutamate-
mediated) neurotransmission, in favour of the latter10. Sei-
zures and epilepsy are usually divided into two groups: 
partial and generalized. Partial or focal seizures have clin-
ical or EEG evidence of local onset and may spread to 
other parts of the brain during a seizure, while general-
ized seizures begin simultaneously in both cerebral hemi-
spheres8. Temporal lobe epilepsy (TlE) is the most com-
mon form of partial epilepsy, probably affecting at least 
20% of all patients with epilepsy11. It is the most common 
form of drug-refractory epilepsy12. Atrophy of mesial tem-
poral structures is well-known to be associated with TlE 
and hippocampal sclerosis, which is the most frequent 
histological abnormality in this form of epilepsy13.
SUDDEn UnExpEcTED DEATH In EpILEpSY
Epilepsy is associated with a two- to three-fold in-
crease in mortality compared to the general population, 
and sudden unexpected death in epilepsy (SUDEP) is the 
most important direct epilepsy-related cause of death8. 
SUDEP is defined as non-traumatic and non-drowning 
death in patients with epilepsy that is sudden, unexpect-
ed, witnessed or unwitnessed, and with or without evi-
dence of a seizure. Also in SUDEP, post mortem examina-
tion does not reveal a toxicological or anatomical cause of 
death (excluding documented status epilepticus)14. Com-
parisons of incidence estimates for SUDEP are difficult, 
since different definitions of SUDEP have been used, not 
all patients have a postmortem examination, and case as-
certainment methods and source populations have var-
ied15. The incidence of SUDEP has been estimated to be 
3.5/1000 person-years in a lamotrigine clinical trial16, 0.5–
1.4/1000 person-years in people with treated epilepsy17, 
5.9/1000 person-years in outpatients with epilepsy at a 
tertiary referral centre18 and 0.35/1000 person-years in a 
population-based study19. The National General Practice 
Study of Epilepsy (NGPSE), a community-based study in 
the United Kingdom, saw the first case of SUDEP after 
11,000 person-years of follow-up20, and the results of the 
Medical research Council Antiepileptic Drug withdrawal 
Study showed that SUDEP is a rare event among patients 
with epilepsy in remission21. Information concerning risk 
factors for SUDEP is conflicting, but potential risk fac-
tors include: early adulthood16, early onset of epilepsy22, 
long duration of epilepsy23, uncontrolled seizures (main-
ly in those with TlE)23,24, high seizure frequency23-25, cer-
tain seizure types23,26, higher numbers of antiepileptic drug 
(AED)22,23,27 and winter temperatures28. Additionally, po-
tential pathomechanisms for SUDEP are unknown, but it 
is very probable that cardiac arrhythmias during and be-
tween seizures, electrolyte disturbances, arrhythmogenic 
drugs or transmission of epileptic activity to the heart via 
the autonomic nervous system potentially play a role29,30.
Following this reasoning, postmortem examinations in 
people dying of SUDEP have found hearts that are dilat-
ed and heavier than expected16,29,31,32 and pulmonary ede-
ma in approximately 50–86% of cases16,26,29,32,33. Further-
more, others have described pathological changes in the 
hearts of those dying with SUDEP, including fibrosis of the 
walls of small coronary arteries, atrophy of cardiomyo-
cytes, myofibrillar degeneration, edema of the conduc-
tive tissue and morphological abnormalities of the cardi-
ac conduction system26,29,31,34,35. These abnormalities may 
be the consequence of repeated hypoxemia and/or may 
be associated with the increase of catecholamines during 
an ictal sympathetic storm29,31,34.
Several studies have assessed the frequency and char-
acter of ictal cardiac rhythm during seizures29,36,37 and the 
most compelling evidence derives from the presence of 
ictal arrhythmias30. when ictal cardiorespiratory vari-
ables were recorded in people with epilepsy, an increase 
in heart rate in 91% of 41 seizures and a transient brady-
cardia in five seizures (four patients) were found38. Anoth-
er study evaluated the eletrocardiographic (ECG) chang-
es during 51 seizures in 43 patients with refractory epilep-
sy39. This showed that 70% of patients had either ECG ab-
normalities (16%), tachycardias (30%), or both (23%) dur-
ing the ictal and/or post-ictal period. These changes may 
all be relevant to the pathophysiology of SUDEP.
results of interictal cardiac investigations have also 
been described. In one study, resting ECGs in 75 patients 
with epilepsy were compared with normal ECGs recorded 
in age-matched patients without cardiac or neurological 
disorders; ventricular rate, Pr interval, QrS duration, and 
QT interval (corrected for heart rate) were compared40. 
Those with epilepsy had higher heart rates and longer QT 
durations than the age-matched controls. heart rate and 
QT duration were, however, not outside the normal range. 
others investigated whether patients with drug refracto-
ry epilepsy have cardiovascular abnormalities that might 
be related to sudden death41. Twenty-three subjects un-
derwent comprehensive cardiovascular evaluations (ECG, 
holter-monitoring, echocardiography, ergometric exercise 
test and myocardial scintigraphy; if abnormalities were 
found, coronary angiography was also performed) before 
and during video-EEG monitoring. ST-segment depression 
was found in 40%, and this was associated with a higher 
maximum heart rate during seizures, suggesting that car-
diac ischemia may occur in these patients. Although inter-
ictal changes in heart rate variability have been described 
in patients with epilepsy, their contribution to SUDEP re-
mains to be determined.
GUSTAVE FLAUBERT: LIFE wITH EpILEpSY
The French novelist Gustave Flaubert (1821-1880) (Fig-





modern novel as a conscious art form and in launching, 
much against his will, the realistic school in France42-47. Fa-
mous for his novel Madame Bovary (1857), Flaubert was a 
perfectionist, who did not make a distinction between a 
beautiful or ugly subject: all was in the style42-47. The idea, 
he argued, only exists by virtue of its form – its elements 
included the perfect word, cunningly contrived and veri-
fied rhythms, and a genuine architectural structure42-47.
Gustave Flaubert was born on December 12, 1821, 
in rouen, France. his father, Achille-Cleophas Flau-
bert was a doctor and an important rouen citizen, and 
his mother, Anne-Justine-Caroline Fleuriot, was a physi-
cian’s daughter46,47. he had an older brother, Achille, and 
a younger sister, Caroline, with whom he had a close re-
lationship43-45. Gustave began to develop his writing skills 
at an early age and wrote plays, which he put on for his 
family at the age of nine or ten46,47. 
In the 1830s Flaubert attended the Collége royal de 
rouen, writing for its newspaper, reading Shakespeare, 
travelling extensively and at the age of fourteen began in 
earnest his own writings, inspired by his unconsummated 
love affair at this time with the much older and married 
Elisa Schlésinger46,47. In this period, he had easy access to 
prostitutes and this led to venereal disease (syphilis) from 
which he never recovered46,47. In 1844 Flaubert had his first 
epileptic seizure, however, some authors described that 
his epilepsy may have started earlier42,44,46. During his first 
seizure, Flaubert was driving a carriage with his brother, 
in front the twinkling lanterns of an obliging carriage and 
a distant inn, when suddenly he fell to the floor as if he 
were dead. It was like ‘‘being swept away in a torrent of 
flames . . . sudden as lightening . . . an instantaneous inter-
ruption of memory . . . a letting go of its entire contents’’ 
42,46. About a month after his first seizure, Flaubert wrote 
to a friend: ‘‘you must know that I had a kind of cerebral 
congestion, in other words a miniature attack of apoplexy, 
accompanied by nervous disorders’’42,45. It is interesting 
to note that this first seizure was followed by four oth-
ers, and Flaubert’s condition gradually worsened42. Clearly, 
he was helplessly crippled by his seizures, which became 
hideous terror for him and recurred at intervals through-
out his life46,47. Flaubert was treated with regular bleed-
ings, mercury massages, and bromide, the antiepileptic 
drug of that time42.
GUSTAVE FLAUBERT: DEATH DUE EpILEpSY?
Based on the preceding considerations, Flaubert’s work 
contains extensive and interesting autobiographic notes. 
on the other hand, the etiology of his epilepsy cannot 
be clarified in biographic material or oral and written tra-
ditions42. however, febrile convulsions, trauma, infection, 
or congenital anomalies with secondary onset of epilep-
sy should be considered42. Moreover, neurosyphilis as a 
potential cause of epilepsy is rather unlikely because of 
the early onset in childhood or adolescence42. Concerning 
the kind of Flaubert’s epilepsy, we are totally in agreement 
with the very elegant considerations evaluated by Arnold 
and colleagues42: “psychopathological considerations sug-
gest primary involvement of mesial temporal lobe struc-
tures with typical findings of ictal and interictal mood be-
havior, as well as unstructured visual aura features such as 
déjà vu and macropsia, which is commonly seen in mesi-
al temporal lobe epilepsy”.
Unfortunately, Flaubert suddenly died in 1880, at the 
age of 5842,46. The circumstances of his death were the sub-
ject of fabulous and mysterious speculations42, since vari-
ous suppositions about his cause of death were made af-
ter Flaubert’s lifetime. In these lines, although some de-
tailed bibliographic reports suggest a stroke as cause of 
his death, an epileptic seizure also be considered respon-
sible by Falubert’s death42. Thus, considering here an ep-
ileptic seizure as cause of Flaubert’s death, we also can 
speculate a new perspective: Could be exist a possible re-
lation between Flaubert’s death and SUDEP?
As we know, the risk of sudden death is clearly increased 
in the epilepsy population, and SUDEP is the most common 
seizure-related category29,30,48,49. SUDEP is mainly, but not ex-
clusively, a problem for patients with chronic uncontrolled 
epilepsy49. Accordingly, among the rarely witnessed cases 
of SUDEP, the majority of patients proved to suffer a partial 
or generalized seizure immediately prior to death, suggest-
ing a seizure-related cardiac or respiratory dysfunction16,30. 






In an elegant largest case-control study, Nilsson and col-
leagues22 demonstrated that seizure frequency is a stron-
gest risk factor for SUDEP. In their study, fifty seven SUDEP 
cases were included, of whom 91% had undergone necrop-
sy. The relative risk of SUDEP increased with number of 
seizures per year and the estimated relative risk was 10.16 
(95% CI 2.94–35.18) in patients with more than 50 seizures 
per year, compared with those with up to two seizures 
per year. In the same way, walczak and co-workers23, in 
a prospective cohort study, determined the incidence of 
and risk factors for SUDEP. The incidence of SUDEP was 
1.21/1,000 patient-years and a progressive risk for SUDEP 
was found with increasing seizure frequency. The authors 
support the idea that tonic-clonic seizures are an impor-
tant proximate cause of SUDEP and concluded that the oc-
currence of as few as 1-3 such seizures per year was asso-
ciated with an increased risk factor23. From a pathophysi-
ological point of view, SUDEP directly result from the oc-
currence of seizures, in particular generalized tonic-clonic 
seizure30. Though the respective role of seizure-induced re-
spiratory and cardiac fatal abnormalities remains uncertain, 
recent studies suggest that high-risk ictal arrhythmias oc-
cur in much greater proportion of patients with refractory 
epilepsy than previously believed, representing the leading 
cause of SUDEP15,30. Quite interesting, as uncontrolled sei-
zures (mainly in those with TlE) and high seizure frequen-
cy are the most important risk factors for SUDEP15,23-25,30, it 
is plausible to believe that factors could influence nega-
tively the cardiovascular system of the patient with epi-
lepsy leading to cardiac abnormalities and hence SUDEP. 
Following these reasoning, as Gustave Flaubert’s case 
points to the possible coexistence of a serious and poorly 
controlled form of temporal lobe epilepsy, it is plausible 
to believe that Flaubert’s death could be associated with 
SUDEP. Although early mortality series at the beginning 
of the 20th century reported deaths from status epilepti-
cus to be more common, deaths associated with repeat-
ed seizures were also recognised49. For example, in 1904, 
Spratling wrote of epilepsy as a disease that, “destroys life 
suddenly and without warning through a single, brief at-
tack…and does so in from 3 to 4% of all who suffer from 
it”49,50 and in this view, Flaubert’s case is not so chronolog-
ical distant from the interesting paper described above. 
Finally, apart from data related here, various diagnoses 
made by medical and nonmedical persons during and af-
ter Flaubert’s lifetime was reviewed by Gastaut group51,52 
and cannot be ruled out. These authors admitted some 
interesting notes: (a) Flaubert suffered from organic and 
not psychogenic epilepsy, more precisely”complex par-
tial epilepsy of occipital-temporal origin, secondary to le-
sion of the left posterior hemisphere with occasional sec-
ondary generalization of seizures.”; (b) Flaubert’s epilep-
sy modified his behaviour without affecting his genius; (c) 
Gustave Flaubert’s case, like Dostoevski’s, should serve as 
a defence witness for the unfortunate epileptics thought 
to be destined for intellectual deterioration only because 
of the repetition of their seizures51,52.
while admitting the deficiencies in our knowledge 
about the circumstances of Flaubert’s disease and death, 
regardless of how it was really evaluated, it seems reason-
able to assume that the risk of sudden death is clearly in-
creased in the epilepsy population actually, and SUDEP is 
the most important direct epilepsy-related cause of death. 
In conclusion, as recently reported53 clarification of risk 
factors and establishment of the mechanisms of SUDEP 
are important for establishing preventative measures for 
SUDEP and for striving for the best control of seizures.
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